CoChat

FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells

Open access
Ni, Li, Yang, Chun-Song, Gioeli, Daniel, Frierson, Henry, Toft, David O., Paschal, Bryce M. · 2010 · Molecular and Cellular Biology

The DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index; 22 of the 48 sources its claims cite were checked for support.

Abstract

Prostate cancer progression to the androgen-independent (AI) state involves acquisition of pathways that allow tumor growth under low-androgen conditions. We hypothesized that expression of molecular chaperones that modulate androgen binding to AR might be altered in prostate cancer and contribute to progression to the AI state. Here, we report that the Hsp90 cochaperone FKBP51 is upregulated in LAPC-4 AI tumors grown in castrated mice and describe a molecular mechanism by which FKBP51 regulates AR activity. Using recombinant proteins, we show that FKBP51 stimulates recruitment of the cochaperone p23 to the ATP-bound form of Hsp90, forming an FKBP51-Hsp90-p23 superchaperone complex. In cells, FKBP51 expression promotes superchaperone complex association with AR and increases the number of AR molecules that undergo androgen binding. FKBP51 stimulates androgen-dependent transcription and cell growth, and FKBP51 is part of a positive feedback loop that is regulated by AR and androgen. Finally, depleting FKBP51 levels by short hairpin RNA reduces the transcript levels of genes regulated by AR and androgen. Because the superchaperone complex plays a critical role in determining the ligand-binding competence and transcription function of AR, it provides an attractive target for inhibiting AR activity in prostate cancer cells.

Overview

CoChat Summary

TL;DR

FKBP51 is overexpressed in an androgen-independent LAPC-4 prostate cancer xenograft model and promotes assembly of an FKBP51-Hsp90-p23 superchaperone complex that increases the number of androgen-bound AR molecules. This provides a feed-forward mechanism for AR signaling and growth under low-androgen conditions, and suggests the superchaperone complex as a therapeutic target.

Key findings

  • FKBP51 protein was elevated about threefold and FKBP51 mRNA 7- to 10-fold in LAPC-4 AI tumors grown in castrated mice versus AD tumors; S100P was upregulated 6- to 15-fold, and PSA was slightly higher in two of three AI xenografts.
  • FKBP51 enhanced androgen-stimulated AR transcription from PSA, probasin, MMTV, and synthetic ARE reporters, while inhibiting dexamethasone-stimulated GR transcription; FK506 blocked FKBP51 enhancement of AR activity.
  • FKBP51 promoted formation of an FKBP51-Hsp90-p23 ternary complex; assembly required ATP or AMP-PNP but not hydrolysis, was inhibited by geldanamycin and FK506, and required the AR ligand-binding domain for AR association.
  • FKBP51 expression increased androgen-binding sites by 38% without changing AR levels or affinity, approximately doubled the PP2A/AR ratio in an androgen-bound AR assay, and FKBP51 knockdown reduced KLK2, PSA, and S100P transcripts; FKBP51 also gave a growth advantage at 50 pM R1881 (P < 0.001).

Methods

  • LAPC-4 xenografts were grown in intact or castrated scid mice; prostate cancer cell lines PC-3 (AR-negative), LNCaP, and CWR22Rv1 (AR-positive) were used, with lentiviral FKBP51 overexpression or shRNA knockdown.
  • AR activity was measured by dual-luciferase reporter assays and real-time PCR for endogenous AR-regulated genes; chaperone complexes were analyzed by immunoprecipitation/immunoblotting and by gel filtration with recombinant FKBP51, Hsp90, and p23.
  • Androgen binding was measured by whole-cell [3H]R1881 binding and a PP2A-AR coimmunoprecipitation assay; growth was measured by MTT assay, with Student t tests and nonlinear regression for Bmax/Kd.

Limitations

  • The paper states no explicit limitations section.
  • Evident from the text: the mechanistic work relies heavily on overexpression in AR-negative PC-3 cells and recombinant proteins, and the in vivo evidence is limited to expression differences in LAPC-4/CWR22 xenografts rather than direct FKBP51 manipulation in tumors.
  • The paper notes that FKBP51 overexpression was not detected in a previous microarray analysis of LAPC-4 xenografts, and that FKBP51 knockout mice lack overt androgen-signaling defects, leaving the normal physiological contribution of FKBP51 unclear.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1128/mcb.01891-08

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

17 Valid · 3 Not valid · 21 Not checked · 88 Own results and interpretations

88 more claims · 1 with their cited sources checked

Create a free account to see all 129 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 26
  • It may state two separate claims as one. 19

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Cited by

See all 155

Metadata

Authors
Ni, L., Yang, C.-S., Gioeli, D., Frierson, H., Toft, D. O., & Paschal, B. M.
Affiliations
  • Center for Cell Signaling
  • Departments of Microbiology
  • University of Virginia (US)
  • Mayo Clinic (US)
Venue
Molecular and Cellular Biology
Published
2010-03
Volume
30
Issue
5
Pages
1243-1253
ISSN
  • 0270-7306 (ISSN-L)
  • 1098-5549
OpenAlex
W2059122555
Cited by
155
References
37
Citations by year
2026: 2 · 2025: 5 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 11 · 2020: 4 · 2019: 8 · 2018: 9 · 2017: 7 · 2016: 10 · 2015: 16 · 2014: 15 · 2013: 14 · 2012: 9
FWCI
11.96
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Molecular and Cellular Biology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense
  • National Cancer Institute (P01CA104106, R01CA124706)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
FKBP51, HSP90, p23, androgen receptor, castration-resistant prostate cancer, androgen receptor signaling, androgen binding, positive feedback loop, molecular chaperones, prostate cancer progression, LAPC4 cells
MeSH terms
Prostaglandin-E Synthases, Tacrolimus Binding Protein 5, Animals, Base Sequence, Humans, Male, Models, Biological, Neoplasm Transplantation, Neoplasms, Hormone-Dependent, Prostatic Neoplasms, Receptors, Androgen, Recombinant Proteins, Transplantation, Heterologous, Signal Transduction, Up-Regulation, Mice, SCID, DNA Primers, HSP90 Heat-Shock Proteins, Intramolecular Oxidoreductases, Tacrolimus Binding Proteins, Cell Line, Tumor, Multiprotein Complexes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.